^
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan
Sensitive: A1 - Approval
No biomarker
Pancreatic Adenocarcinoma
LV5FU2
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
CAPOX
Sensitive: A2 - Guideline
NTRK3 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Pancreatic Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
erlotinib
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
capecitabine
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil + capecitabine
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + capecitabine
Sensitive: A2 - Guideline
BRCA1 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
BRCA2 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
PALB2 mutation
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Pancreatic Adenocarcinoma
5-fluorouracil + irinotecan
Sensitive: A2 - Guideline
NTRK1 fusion
Pancreatic Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
MSI-H/dMMR
Pancreatic Adenocarcinoma
pembrolizumab
Sensitive: A2 - Guideline
NTRK2 fusion
Pancreatic Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: C1 - Off-label
RET fusion
Pancreatic Adenocarcinoma
pralsetinib
Sensitive: C1 - Off-label
TMB-H
Pancreatic Adenocarcinoma
pembrolizumab
Sensitive: C1 - Off-label
KRAS G12R
Pancreatic Adenocarcinoma
selumetinib
Sensitive: C3 – Early Trials
KRAS mutation
Pancreatic Adenocarcinoma
trametinib
Sensitive: C3 – Early Trials
HER-2 expression
Pancreatic Adenocarcinoma
trastuzumab + erlotinib + gemcitabine
Sensitive: C3 – Early Trials
EGFR expression
Pancreatic Adenocarcinoma
trastuzumab + erlotinib
Sensitive: C3 – Early Trials
CDH1 expression
Pancreatic Adenocarcinoma
erlotinib + selumetinib
Sensitive: C3 – Early Trials
SMAD4 deletion
Pancreatic Adenocarcinoma
gemcitabine + albumin-bound paclitaxel + hydroxychloroquine
Sensitive: C3 – Early Trials
TP53 mutation
Pancreatic Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
BRCA2 mutation
Pancreatic Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
TP53 mutation
Pancreatic Adenocarcinoma
FOLFOX
Sensitive: C3 – Early Trials
BRCA2 mutation
Pancreatic Adenocarcinoma
FOLFOX
Sensitive: C3 – Early Trials
SEL1L-NTRK1 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: C4 – Case Studies
SEL1L-NTRK1 fusion
Pancreatic Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Resistant: C4 – Case Studies
PD-L1 expression + TMB-H + FANCA deletion
Pancreatic Adenocarcinoma
toripalimab
Sensitive: C4 – Case Studies
PD-L1 expression + TMB-H + FANCA deletion
Pancreatic Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: C4 – Case Studies
EGFR exon 19 mutation
Pancreatic Adenocarcinoma
erlotinib
Sensitive: C4 – Case Studies
BRCA2 mutation + CHEK2 mutation
Pancreatic Adenocarcinoma
FOLFIRINOX
Sensitive: C4 – Case Studies
BRCA2 1153insT
Pancreatic Adenocarcinoma
cisplatin + gemcitabine
Sensitive: C4 – Case Studies
KRAS mutation
Pancreatic Adenocarcinoma
cobimetinib
Sensitive: D – Preclinical
FAM83D overexpression
Pancreatic Adenocarcinoma
gemcitabine
Resistant: D – Preclinical
PTGR1 elevation + HRD
Pancreatic Adenocarcinoma
LP-184
Sensitive: D – Preclinical
KRAS G13D
Pancreatic Adenocarcinoma
ASN007
Sensitive: D – Preclinical
KRAS G12C
Pancreatic Adenocarcinoma
ASN007
Sensitive: D – Preclinical